Bfsg LLC Invests $3 Million in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Bfsg LLC acquired a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 150,927 shares of the biopharmaceutical company’s stock, valued at approximately $3,000,000. Bfsg LLC owned 0.13% of Catalyst Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its position in shares of Catalyst Pharmaceuticals by 62.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 681 shares in the last quarter. CWM LLC boosted its holdings in Catalyst Pharmaceuticals by 686.5% during the second quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock worth $63,000 after buying an additional 3,549 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in Catalyst Pharmaceuticals in the second quarter worth approximately $70,000. SG Americas Securities LLC bought a new position in shares of Catalyst Pharmaceuticals in the third quarter valued at $173,000. Finally, Headlands Technologies LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the 1st quarter valued at $154,000. Institutional investors own 79.22% of the company’s stock.

Analyst Ratings Changes

CPRX has been the topic of a number of recent analyst reports. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Truist Financial boosted their price objective on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, August 9th. HC Wainwright raised their target price on shares of Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, Citigroup lifted their target price on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $29.50.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Steve Miller sold 150,000 shares of the company’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total value of $3,052,500.00. Following the transaction, the insider now directly owns 675,124 shares of the company’s stock, valued at $13,738,773.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, Director David S. Tierney sold 15,000 shares of Catalyst Pharmaceuticals stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total value of $301,500.00. Following the completion of the sale, the director now owns 348,874 shares of the company’s stock, valued at approximately $7,012,367.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Steve Miller sold 150,000 shares of the stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the transaction, the insider now directly owns 675,124 shares in the company, valued at $13,738,773.40. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 201,058 shares of company stock valued at $4,018,188. Insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

NASDAQ CPRX opened at $21.67 on Thursday. The firm has a market capitalization of $2.56 billion, a price-to-earnings ratio of 40.13, a price-to-earnings-growth ratio of 3.18 and a beta of 0.76. The company has a 50 day simple moving average of $19.97 and a 200-day simple moving average of $17.29. Catalyst Pharmaceuticals, Inc. has a 52-week low of $11.89 and a 52-week high of $21.85.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.13. Catalyst Pharmaceuticals had a net margin of 15.69% and a return on equity of 27.77%. The company had revenue of $122.71 million during the quarter, compared to the consensus estimate of $111.76 million. On average, analysts predict that Catalyst Pharmaceuticals, Inc. will post 1.82 EPS for the current year.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.